Alimta

... Eli Lilly "buy" | newratings.com a.red{text-decoration: underline;font-size:12px;font-family: Arial, Helvetica, sans-serif;color: red; line-height: 19px} a.red:visited{text-decoration: underline;font-size:12px;font-family: Arial, Helvetica, sans-serif;color: red line-height: 19px} a.green{text-decoration: underline;font-size:12px;font-family: Arial, Helvetica, sans-serif;color: green; line-height: 19px} a.green:visited{text-decoration: underline;font-size:12px;font-family: Arial, Helvetica, sans-serif;color: green; line-height: 19px} a:link {text-decoration: underline;} a.NEWSlink{text-decoration: underline;font-size:12px;font-family: Arial, Helvetica, sans-serif;color: #006699; line-height: 19px} a.NEWSlink:visited{text-decoration: underline;font-size:12px;font-family: "Arial","Arial";color: #006699} a:active {text-decoration: underline;} a:visited {text-decoration: underline;} a:hover {text-decoration: underline; color: #333333;} a.menu_on:link {text-decoration: underline; color: #006699; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; } a.menu_on:active {text-decoration: underline; color: #006699; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; } a.menu_on:visited {text-decoration: underline; color: #006699; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; } a.menu_on:hover {text-decoration: underline; color: #333333; font-family: Arial, Helvetica, sans-serif; font-size: 9pt; } a.menu_off:link {text-decoration: underline; color:...

... Eli Lilly Set For Sales Growth - Forbes.com '); } if (document.cookie.indexOf('partner_session=msnbc') !

= -1) { var _rsCI='us-forbes'; var _rsCG='msnbc_hat_test'; var _rsDT=1; var _rsSI=escape(window.location); var _rsLP=location.protocol.indexOf('https')=4) { var _rsRD=(new Date()).getTime(); var _rsSE=1; var _rsSV=''; var _rsSM=1.0; _rsCL=''; } else { _rsCL=''; } //document.write(_rsCL); document.write(''); } // -> Jump | Free Trial Issue Search Quote Select Section Home Investment Newsletters Polls & Discussions Premium Tools Special Reports Video & Audio IT Research Library IT Product & Service Search Forbes Digital Tool Business -Manufacturing -Technology -Commerce -Services -Energy -Healthcare -Logistics Technology -E-Business -Enterprise Tech -Infoimaging -Intelligent Infrastructure -Personal Tech -Sciences & Medicine -Wireless -CIO Network -Digital Entertainment Markets -Equities -Economy -Commodities -Bonds -Emerging Markets -Currencies Entrepreneurs -Finance -Human Resources -Law & Taxation -Sales & Marketing -Management -Technology Work -Careers -Compensation -Management Lists -Companies -Forbes Global 2000 -200 Best Small Cos.

-400 Best Big Cos.

-Largest Private Cos.

-People -World's Richest People -100 Top Celebrities -400 Richest Americans -Best Paid CEOs -Places -Best Places Personal Finance -Estate ...

... The Japan Times Online Site Map Sunday, November 20, 2005 CLASSIFIED ADS WEEKEND SCENE SUBSCRIBE BULLETIN BOARD SHUKAN ST WEEKLY BOOK SPORTS LIFE MOVIES MUSIC - Subscribe - Home News Business Sports - Sumo Movie reviews - Listings - Maps Music Life in Japan - Popular culture - Media - Education - Travel - Environment - Gourmet Art - Books - Photography - Dance - Theater - Crafts Op-Ed - Letters Cartoons Weekly round up Festivals Cabinet profiles Links News calendar - Classified ads New!

- New!

Asbestos drug gets fast-track status The Health, Labor and Welfare Ministry has decided to shorten the review period for a drug to treat mesothelioma, a type of lung cancer caused by asbestos exposure, it was learned Saturday.

Under its priority system for drug evaluation, the ministry will shorten the review period on The average time to review a new drug is two years.

The ministry made the decision amid expanding health damage to people from asbestos.

There is no absolute cure for the disease.

Eli Lily Japan K.K., the Japanese arm of the U.S.

pharmaceutical company, is conducting therapeutic testing on The company is expected to submit an application to the ministry for import approval for the drug next year....